AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7795283
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg nocte)
Trial: 2693231
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g tds)
Trial: 356245
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren) 125 mg daily
Trial: 27994091
Drug: Etanercept (E)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (E) therapy
Trial: 27994091
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (T)
Trial: 25804278
Drug: Thrombogenicity indices
RxNorm normalized name: Hemidesmus indicus root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombogenicity indices and cell adhesion molecules
Trial: 23482999
Drug: 1% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mepivacaine (0.9 ml injected)
Trial: 9014960
Drug: Training twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training twice a week (2x/wk, n = 17)
Trial: 8204875
Drug: Cranial radiotherapy
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial radiotherapy (cRT) plus prolonged triple intrathecal (IT) therapy with methotrexate (MTX), cytarabine, and prednisone.
Trial: 8204875
Drug: No cranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cranial radiotherapy (cRT) but prolonged triple IT therapy.
Trial: 8204875
Drug: Neither cRT
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither cRT nor prolonged triple IT therapy.
Trial: 23948001
Drug: Motivational tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational tobacco cessation treatment combined with nicotine replacement
Trial: 22329473
Drug: Memantine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (starting dose of 5 mg increased up to 20 mg over four weeks, then stable dose of 20 mg from four to eight weeks)
Trial: 22329473
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching pill)
Trial: 20151970
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion SR 150 mg/daily
Trial: 19375168
Drug: Intravitreal perfluoropropane
RxNorm normalized name: pentafluoropropane
DrugBank: Pentafluoropropane (DB13117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal perfluoropropane (C3F8) gas injection (group A)
Trial: 16974189
Drug: bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion XL (300-450 mg/d)
Trial: 16974189
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR (150-225 mg/d)
Trial: 12764337
Drug: Cyclobenzaprine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine with ibuprofen
Trial: 11195030
Drug: 0 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 microg LPS (saline treatment)
Trial: 8349477
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg)
Trial: 30098076
Drug: Melatonin 6
RxNorm normalized name: melatonin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 6 mg/d orally from 3 days before surgery to 3 days after surgery
Trial: 30098076
Drug: Vehicle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle treatment in rats
Trial: 30098076
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo treatment in patients
Trial: 26223941
Drug: Teduglutide (TED)
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide (TED) 0.05 mg/kg daily subcutaneous
Trial: 24258773
Drug: IV famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV famotidine 12 mg/m²
Trial: 24258773
Drug: IV ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ranitidine 60 mg/m²
Trial: 22321909
Drug: Propranolol (noradrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (noradrenergic antagonist)
Trial: 20147856
Drug: Oral S-1
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 1 and 8 (arm A)
Trial: 20147856
Drug: Oral S-1
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 8 and 15 (arm B)
Trial: 2029414
Drug: External-beam radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: External-beam radiation therapy
Trial: 31931924
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (20 ml 0.5% bupivacaine in 480 ml normal saline)
Trial: 25899791
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg, single oral dose)
Trial: 24042024
Drug: Any oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any oral NSAIDs
Trial: 24042024
Drug: Highest users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest users of non-aspirin NSAIDs
Trial: 24042024
Drug: Highest users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest users of low-dose aspirin
Trial: 19873914
Drug: Scalp point
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp point injection of 0.5‐1 mL brain protein hydrolysate into acupoints (Baihui (GV 20), Fengchi (GB 20), motor area)
Trial: 19873914
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of 10 mL brain protein hydrolysate
Trial: 18294442
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg every 12 h for 10 days)
Trial: 18294442
Drug: Nitrofurantoin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (100 mg every 6 h for 10 days)
Trial: 18294442
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg every 12 h for 10 days)
Trial: 15591651
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) at 10 mg/kg
Trial: 11204663
Drug: Oxaliplatin as
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin as monotherapy
Trial: 21872935
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.3 mg)
Trial: 21872935
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (verteporfin photodynamic therapy [PDT] and sham intravitreal injections)
Trial: 17274862
Drug: Cocaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 4% solution
Trial: 12546311
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral granisetron plus intravenous dexamethasone (gran/dex)
Trial: 12546311
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide plus intravenous dexamethasone (met/dex)
Trial: 10051936
Drug: Endotracheal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal lidocaine (0.4 ml lidocaine 8% spray)
Trial: 10051936
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (32 mg)
Trial: 2513143
Drug: Flecainide (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (median dose 300 mg/day)
Trial: 17095725
Drug: Rho kinase
RxNorm normalized name: Rho(D) immune globulin Injection [WinRho]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rho kinase inhibitor, fasudil
Trial: 11342364
Drug: CEMP (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) chemotherapy protocol
Trial: 11342364
Drug: CEMP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEMP chemotherapy protocol
Trial: 7936476
Drug: Lisinopril (10mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10mg, 20mg, 40mg daily)
Trial: 7936476
Drug: Captopril (25mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25mg, 50mg, 100mg daily)
Trial: 14155162
Drug: Methysergide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methysergide (2 mg, three times a day orally for 5 weeks)
Trial: 14155162
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical dosage and duration as methysergide)
Trial: 31286645
Drug: TRV734 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV734 125 mg
Trial: 31286645
Drug: TRV734 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV734 125 mg (drug in capsule after high-fat meal)
Trial: 31286645
Drug: TRV734 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV734 (various doses 2 to 250 mg)
Trial: 31286645
Drug: TRV734 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV734 (various doses)
Trial: 31596672
Drug: Type IV
RxNorm normalized name: Collagen type IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type IV recurrence (any combination of Types I-III, or multiple recurrences within a single Type)
Trial: 26151924
Drug: DHA (1470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (1470 mg/day) + EPA (147 mg/day)
Trial: 23541756
Drug: ISIS 333611
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 333611 (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg)
Trial: 16573261
Drug: 1% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metronidazole cream
Trial: 16573261
Drug: metronidazole creams
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazole creams
Trial: 6214216
Drug: Cleansing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing agent without abrasive granules
Trial: 29206921
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg modafinil
Trial: 29206921
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg methylphenidate
Trial: 29206921
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg 3,4‐methylenedioxymethamphetamine
Trial: 26374918
Drug: Traditional diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional diuretic therapy
Trial: 23349882
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta (IFNB) treatment
Trial: 21592048
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg RSG XR
Trial: 21592048
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg RSG XR
Trial: 12840087
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous peripheral-blood hematopoietic progenitor-cell transplantation (6 g of cyclophosphamide, 480 mg of thiotepa, 1600 mg of carboplatin)
Trial: 12840087
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy (FEC every three weeks for five courses)
Trial: 12840087
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy in patients with 10 or more positive nodes
Trial: 12840087
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy in patients with 10 or more positive nodes
Trial: 11043056
Drug: Leflunomide (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (loading dose of 100 mg orally for three days, followed by 20 mg daily)
Trial: 11043056
Drug: Methotrexate or
RxNorm normalized name: methotrexate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate or sulphasalazine (previous treatments)
Trial: 2069245
Drug: Epidural pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural pethidine 25 mg in normal saline
Trial: 27633651
Drug: Multigrowth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multigrowth factor (MGF) cream
Trial: 21919966
Drug: Iloprost administered
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost administered for seven days after transplantation
Trial: 21919966
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no iloprost treatment)
Trial: 19180065
Drug: Usual lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual lifestyle treatment program
Trial: 19180065
Drug: Standard lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lifestyle treatment program
Trial: 19180065
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle treatment program
Trial: 17728363
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) (1.5-2.0 g/day)
Trial: 17728363
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (CTX) (0.75-1.0 g/m2)
Trial: 15678245
Drug: ANP (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP (60 pmol/100 mL FAV/min)
Trial: 15678245
Drug: Short-term infusions
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term infusions of ANP
Trial: 15678245
Drug: Long-term infusions
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term infusions of ANP
Trial: 15678245
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of ANP, BNP, and CNP
Trial: 10037839
Drug: hANP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hANP administered after operation until leaving ICU
Trial: 10037839
Drug: No hANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hANP administered (Control)
Trial: 7619666
Drug: Oral dextromethorphan
RxNorm normalized name: dextromethorphan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextromethorphan 30 mg
Trial: 7619666
Drug: Inhaled dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled dextromethorphan (1, 3, and 30 mg)
Trial: 7619666
Drug: Oral matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matched placebo
Trial: 7619666
Drug: Matched inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched inhaled placebo
Trial: 2244080
Drug: Flexible group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible group sequential testing using a Lan and DeMets procedure with permutation test
Trial: 28327453
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation plus active oxybutynin administration
Trial: 28327453
Drug: Active oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oxybutynin administration
Trial: 19419331
Drug: Standard caspofungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard caspofungin regimen (50 mg/day after a 70 mg dose on day 1)
Trial: 19419331
Drug: High-dose caspofungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caspofungin regimen (150 mg/day)
Trial: 19419331
Drug: High-dose caspofungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caspofungin regimen
Trial: 15496641
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg subcutaneously twice weekly) plus Methotrexate (weekly oral dose, median 20 mg)
Trial: 11778664
Drug: 2,3-dimercapto-1-propanesulfonate 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,3-dimercapto-1-propanesulfonate 100-mg capsules 4 times a day for 1 week, repeated in the 3rd, 5th, and 7th week
Trial: 11778664
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules resembling 2,3-dimercapto-1-propanesulfonate
Trial: 9102259
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for colon carcinoma
Trial: 9102259
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for rectal carcinoma
Trial: 22278627
Drug: Daily dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dialysis for 1 week after standard hemodialysis (HD) for 1 week
Trial: 22278627
Drug: Standard hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hemodialysis (HD) for 1 week after daily dialysis for 1 week
Trial: 15667660
Drug: Doxycycline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (10 and 100 microg/ml) - ex-vivo treatment
Trial: 7594338
Drug: Lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LPZ) 30 mg q.d. for 8 weeks in GU and 6 weeks in DU
Trial: 7594338
Drug: Roxatidine (R)
RxNorm normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine (R) 75 mg b.i.d. for 8 weeks in GU and 6 weeks in DU
Trial: 6107452
Drug: oxprenolol, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxprenolol, 40 mg three times a day
Trial: 6107452
Drug: disopyramide phosphate,
RxNorm normalized name: Disopyramide Phosphate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: disopyramide phosphate, 150 mg three times a day
Trial: 6306388
Drug: HCTZ 50
RxNorm normalized name: HCTZ 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 50 mg/day
Trial: 6306388
Drug: MK-421 10
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-421 10 mg/day
Trial: 6306388
Drug: HCTZ 50
RxNorm normalized name: HCTZ 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 50 mg/day plus MK-421 10 mg/day
Trial: 31185057
Drug: Park Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Park Prescription intervention including face-to-face counseling and weekly structured exercise sessions in the park.
Trial: 27711083
Drug: WBRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT plus vandetanib (100 mg once daily for 3 weeks)
Trial: 17652648
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg per kilogram of body weight)
Trial: 12387530
Drug: Home-made oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-made oral supplement (group A)
Trial: 12387530
Drug: Home-made oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-made oral supplement (group B)
Trial: 10460068
Drug: Initial intravenous
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial intravenous dose of 50 mg ranitidine; followed by either repeated injections (50 mg every 6 hours) or a continuous infusion (50 mg plus 0.125 mg/kg/h)
Trial: 8528053
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose groups
Trial: 2192011
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b (1.5 x 10(6) IU) injected intralesionally plus podophyllin resin applied topically once weekly for 3 weeks
Trial: 31856760
Drug: Naloxone (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.05 μg·kg−1·h−1)
Trial: 21593283
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of celiprolol (100 mg)